Breaking News
Start for Free 0
💥 Fed cuts sparks mid cap boom! ProPicks AI scores with 4 stocks +23% each. Get October’s update first. Pick Stocks with AI
Close

Db Bio Health Care 30 Bond Balanced 1 Cp2 (0P0000Z1VX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,055.220 +6.230    +0.59%
26/09 - Closed. Currency in KRW ( Disclaimer )
  • Morningstar Rating:
  • Total Assets: 9.23B
Type:  Fund
Market:  South Korea
Issuer:  DB Asset Management
Asset Class:  Equity
Dongbu Bio Health Care 30 Bond Balanced 1 CP2 1,055.220 +6.230 +0.59%

0P0000Z1VX Holdings

 
Comprehensive information about top holdings and Key Holding Information for the Dongbu Bio Health Care 30 Bond Balanced 1 CP2 (0P0000Z1VX) fund. Our Dongbu Bio Health Care 30 Bond Balanced 1 CP2 portfolio information includes stock holdings, annual turnover, top 10 holdings, sector and asset allocation.

Asset Allocation

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Name  Net %  Long %  Short %
Cash 15.710 15.990 0.280
Shares 29.670 29.670 0.000
Bonds 54.630 54.630 0.000

 Style Box

Value & Growth Measures

Ratios Value Category Average
P/E Ratio 29.651 15.448
Price to Book 2.392 1.058
Price to Sales 1.728 0.942
Price to Cash Flow 11.982 6.431
Dividend Yield 0.503 2.587
5 Years Earnings Growth 25.686 19.418

Sector Allocation

Name  Net % Category Average
Healthcare 78.940 9.748
Technology 8.940 33.213
Industrials 5.570 20.209
Communication Services 3.280 6.607
Consumer Cyclical 1.880 9.715
Consumer Defensive 1.390 6.290

Region Allocation

  • Asia
  • Developed Markets

Top Holdings

Number of long holdings: 58

Number of short holdings: 1

Name ISIN Weight % Last Change %
KTB04250-2412(22-15) KR103503GCC6 54.63 - -
  Alteogen KR7196170005 3.91 332,000 -2.64%
  Celltrion KR7068270008 2.87 194,800 -3.56%
  Samsung Biologics KR7207940008 2.82 986,000 -6.27%
  Yuhan KR7000100008 2.39 146,100 -3.44%
  LigaChem Biosciences KR7141080002 1.74 97,800 -5.05%
  Samsung Electronics Co KR7005930003 1.52 64,200 -0.77%
  Hanmi Pharm Co KR7128940004 1.22 313,500 -7.25%
  ABL Bio KR7298380007 0.88 30,150 -3.05%
  Sk Biopharma KR7326030004 0.81 103,400 -4.17%

Top Equity Funds by DB Asset Management

  Name Rating Total Assets YTD% 3Y% 10Y%
  Dongbu Bio Health Care Equity 1 A 137.99B 27.07 1.16 7.93
  Dongbu Bio Health Care Equity 1 C5 137.99B 26.68 0.68 7.42
  Dongbu Bio Health Care Equity 1 CE 137.99B 26.68 0.68 7.44
  Dongbu Sunrising Index Alpha Eq CE 15.08B 1.94 -2.34 5.47
  Dongbu Sunrising Index Alpha Eq A 15.08B 2.07 -2.17 5.65
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P0000Z1VX Comments

Write your thoughts about Db Bio Health Care 30 Bond Balanced 1 Cp2
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email